StemInov
Vandoeuvre-lès-nancy
About StemInov
StemInov is a biotechnology company that focuses on the development of stem cell therapies for inflammatory diseases. The company's primary focus is on critical care, specifically septic shock and Acute Respiratory Distress Syndrome (ARDS). StemInov's approach is based on robust preclinical data and widely accepted safety measures. The company is developing an off-the-shelf and allogenic cell therapy. StemInov is also working on a drug-based therapy using mesenchymatous stem cells from Wharton's jelly (WJ-MSC).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $12.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2025)
- Website: steminov.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Life Science, STEM Education
Social Profiles
Canonical: https://fsome.com/organization/steminov-27408 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.